These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26018599)

  • 41. A preliminary randomised controlled study of short-term Antrodia cinnamomea treatment combined with chemotherapy for patients with advanced cancer.
    Tsai MY; Hung YC; Chen YH; Chen YH; Huang YC; Kao CW; Su YL; Chiu HH; Rau KM
    BMC Complement Altern Med; 2016 Aug; 16(1):322. PubMed ID: 27565426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study.
    Czito BG; Deming DA; Jameson GS; Mulcahy MF; Vaghefi H; Dudley MW; Holen KD; DeLuca A; Mittapalli RK; Munasinghe W; He L; Zalcberg JR; Ngan SY; Komarnitsky P; Michael M
    Lancet Gastroenterol Hepatol; 2017 Jun; 2(6):418-426. PubMed ID: 28497757
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Chanan-Khan AA; Zaritskey A; Egyed M; Vokurka S; Semochkin S; Schuh A; Kassis J; Simpson D; Zhang J; Purse B; Foà R
    Lancet Haematol; 2017 Nov; 4(11):e534-e543. PubMed ID: 28958469
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Phase I/IIA randomized study of PHY906, a novel herbal agent, as a modulator of chemotherapy in patients with advanced colorectal cancer.
    Farrell MP; Kummar S
    Clin Colorectal Cancer; 2003 Feb; 2(4):253-6. PubMed ID: 12620148
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Can probiotic yogurt prevent diarrhoea in children on antibiotics? A double-blind, randomised, placebo-controlled study.
    Fox MJ; Ahuja KD; Robertson IK; Ball MJ; Eri RD
    BMJ Open; 2015 Jan; 5(1):e006474. PubMed ID: 25588782
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Systemic anti-cancer therapy-induced diarrhoea.
    Forde C
    Br J Hosp Med (Lond); 2017 Sep; 78(9):C135-C139. PubMed ID: 28898154
    [No Abstract]   [Full Text] [Related]  

  • 48. Pycnogenol may alleviate adverse effects in oncologic treatment.
    Belcaro G; Cesarone MR; Genovesi D; Ledda A; Vinciguerra G; Ricci A; Pellegrini L; Gizzi G; Ippolito E; Dugall M; Cacchio M; Di Renzo A; Stuard S
    Panminerva Med; 2008 Sep; 50(3):227-34. PubMed ID: 18927527
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
    Pignata S; Scambia G; Katsaros D; Gallo C; Pujade-Lauraine E; De Placido S; Bologna A; Weber B; Raspagliesi F; Panici PB; Cormio G; Sorio R; Cavazzini MG; Ferrandina G; Breda E; Murgia V; Sacco C; Cinieri S; Salutari V; Ricci C; Pisano C; Greggi S; Lauria R; Lorusso D; Marchetti C; Selvaggi L; Signoriello S; Piccirillo MC; Di Maio M; Perrone F; ; ; ; ;
    Lancet Oncol; 2014 Apr; 15(4):396-405. PubMed ID: 24582486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
    Krop IE; Kim SB; Martin AG; LoRusso PM; Ferrero JM; Badovinac-Crnjevic T; Hoersch S; Smitt M; Wildiers H
    Lancet Oncol; 2017 Jun; 18(6):743-754. PubMed ID: 28526538
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of diosmectite in acute childhood diarrhoea: a meta-analysis.
    Das RR; Sankar J; Naik SS
    Arch Dis Child; 2015 Jul; 100(7):704-12. PubMed ID: 25784748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer.
    Harder H; Shilling VM; May SF; Cella D; Schmid P; Fallowfield LJ
    Breast Cancer Res Treat; 2020 Oct; 183(3):629-638. PubMed ID: 32720113
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The assessment and management of cancer treatment-related diarrhea.
    O'Brien BE; Kaklamani VG; Benson AB
    Clin Colorectal Cancer; 2005 Mar; 4(6):375-81; discussion 382-3. PubMed ID: 15807929
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Non-pharmacological interventions for chemotherapy-induced diarrhoea and constipation management: A scoping review.
    Phung TH; Pitt E; Alexander K; Bradford N
    Eur J Oncol Nurs; 2024 Feb; 68():102485. PubMed ID: 38104513
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Constipation and diarrhea in patients with cancer.
    Solomon R; Cherny NI
    Cancer J; 2006; 12(5):355-64. PubMed ID: 17034672
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New strategies for the prevention and reduction of cancer treatment-induced diarrhea.
    Anthony L
    Semin Oncol Nurs; 2003 Nov; 19(4 Suppl 3):17-21. PubMed ID: 14702929
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of a symptom diary during chemotherapy: A mixed-methods evaluation of the patient perspective.
    Coolbrandt A; Steffens E; Wildiers H; Bruyninckx E; Verslype C; Milisen K
    Eur J Oncol Nurs; 2017 Dec; 31():37-45. PubMed ID: 29173825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Complications of systemic therapy--gut infections and acute diarrhoea.
    Lee DL; Anthoney A
    Clin Med (Lond); 2014 Oct; 14(5):528-31. PubMed ID: 25301916
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.